Key statistics
As of last trade Axsome Therapeutics Inc (AXSM:NMQ) traded at 94.84, -3.62% below its 52-week high of 98.40, set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 92.89 |
---|---|
High | 94.84 |
Low | 91.80 |
Bid | 94.71 |
Offer | 94.95 |
Previous close | 91.54 |
Average volume | 424.33k |
---|---|
Shares outstanding | 48.00m |
Free float | 39.46m |
P/E (TTM) | -- |
Market cap | 4.39bn USD |
EPS (TTM) | -6.51 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 16:25 BST.
More ▼
- Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
- Axsome Therapeutics to Participate in Investor Conferences in September
- Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
- Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
- Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
- Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
- Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
More ▼